Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799696 | 1.00 | TRPV1 (0.66) | TRPV1MAPTMEN1NPC1LMNA | |
| SCHEMBL1799320 | 0.90 | TRPV1 (0.59) | TRPV1MAPTMEN1NPC1LMNA | |
| SCHEMBL1799317 | 0.90 | TRPV1 (0.59) | TRPV1MAPTMEN1NPC1LMNA | |
| SCHEMBL1797991 | 0.89 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL1797989 | 0.89 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL1796362 | 0.88 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL1796366 | 0.88 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL12350058 | 0.88 | TRPV1 (0.64) | TRPV1MAPTTP53 | |
| SCHEMBL1797615 | 0.87 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL1796623 | 0.87 | TRPV1 (0.85) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | claimed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | claimed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | claimed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885MAPT 4694/4885MEN1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.